Impact of pharmacist antimicrobial dosing adjustments in septic patients on continuous renal replacement therapy in an intensive care unit

Scandinavian Journal of Infectious Diseases

Volumn 45, Issue 12, 2013, Pages 891-899

  Jiang, Sai Ping ^a   Zhu, Zheng Yi ^a   Ma, Kui Fen ^a   Zheng, Xia ^a   Lu, Xiao Yang ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Antimicrobial dosing adjustment; Continuous renal replacement therapy; Outcomes; Pharmacist interventions; Septic patients

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BETA LACTAM ANTIBIOTIC; CASPOFUNGIN; CEFEPIME; CEFOPERAZONE PLUS SULBACTAM; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; FLUCONAZOLE; FOSFOMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; VANCOMYCIN; VORICONAZOLE;

ANTIBIOTIC THERAPY; ARTICLE; CONTINUOUS RENAL REPLACEMENT THERAPY; COST CONTROL; DRUG COST; INTENSIVE CARE UNIT; LENGTH OF STAY; PHARMACIST; RECOMMENDED DRUG DOSE; SEPSIS; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTI-INFECTIVE AGENTS; FEMALE; HUMANS; INTENSIVE CARE; MALE; MEDICATION ERRORS; MIDDLE AGED; PHARMACISTS; RENAL REPLACEMENT THERAPY; SEPSIS;

EID: 84887983442     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2013.827338     Document Type: Article

References (27)

1. Rahman T M, Treacher D. M anagement of acute renal failure on the intensive care unit. Clin Med 2002; 2: 108-13.
2. Kim WY, Huh JW, Lim CM, Koh Y, Hong SB. A nalysis of progression in risk, injury, failure, loss, and end-stage renal disease classifi cation on outcome in patients with severe sepsis and septic shock. J Crit Care 2012; 27: 104.e1-7
3. Trotman R L, Williamson J C, Shoemaker D M, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005; 41: 1159-66.
4. Bugge JF. P harmacokinetics and drug dosing adjustments during continuous venovenous hemofi ltration or hemodiafi ltration in critically ill patients. Acta Anaesthesiol Scand 2001; 45: 929-34.
5. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The infl uence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146-55.
6. Francisco J, González DM, Ricard F. A ppropriate antibiotic dosing in severe sepsis and acute renal failure: factors to consider. Crit Care 2011; 15: 175.
7. Roberts J A, Kruger P, Paterson D L, Lipman J. A ntibiotic resistance - what ' s dosing got to do with it?. Crit Care Med 2008; 36: 2433-40.
8. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. SCCM/ESICM/ACCP/ATS/SIS: International Sepsis Defi nitions Conference. Crit Care Med 2003; 31: 1250-6.
9. Choi G, Gomersall CD, Tian Q, Joynt GM, Li A M, Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Blood Purif 2010; 30: 195-212.
10. Seyler L, Cotton F, Taccone FS, De Backer D, Macours P, Vincent JL, et al. Recommended -lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care 2011; 15: R137.
11. Glossop A, Seidel J. D osing regimes for antimicrobials during continuous veno-venous haemofi ltration (CVVH). J Intensive Care Soc 2008; 9: 160-5.
12. Gavaza P, Brown CM, Lawson KA, Rascati KL, Steinhardt M, Wilson JP. Pharmacist reporting of serious adverse drug events to the Food and Drug Administration. J Am Pharm Assoc (2003) 2012; 52: e109-12.
13. Nebeker J R, Barach P, Samore M H. C larifying adverse drug events: a clinician ' s guide to terminology, documentation, and reporting. Ann Intern Med 2004; 140: 795-801.
14. Naranjo C A, Busto U, Sellers E M, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
15. Nebeker JR, Hurdle JF, Hoffman JM, Roth B, Weir CR, Samore MH. Developing a taxonomy for research in adverse drug events: potholes and signposts. J Am Med Inform Assoc 2002; 9: S80-5.
16. Park SK, Chun HJ, Kim DW, Im T H, Hong HJ, Hyeong-Joong Y. Acute Physiology and Chronic Health Evaluation II and Simplifi ed Acute Physiology Score II in predicting hospital mortality of neurosurgical intensive care unit patients. J Korean Med Sci 2009; 24: 420-6.
17. Miet S. D rug dosing in continuous renal replacement therapy: general rules. Curr Opin Crit Care 2007; 13: 645-51.
18. Roberts DM, Roberts J A, Roberts M S. V ariability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med 2012; 40: 1523-8.
19. MacLaren R, Bond C A, Martin S J, Fike D. C linical and economic outcomes of involving pharmacists in the direct care of critically ill patients with infections. Crit Care Med 2008; 36: 3184-9.
20. Garnacho-Montero J, Ortiz-Leyba C, Herrera-Melero I, Aldabó-Pall á s T, Cayuela-Dominguez A, Marquez-Vacaro JA, et al. Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched cohort study. J Antimicrob Chemother 2008; 61: 436-41.
21. Kopp BJ, Mrsan M, Erstad BL, Duby JJ. C ost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health Syst Pharm 2007; 64: 2483-7.
22. Klopotowska JE, Kuiper R, van Kan HJ, de Pont AC, Dijkgraaf MG, Lie-A-Huen L, et al. On-ward participation of a hospital pharmacist in a Dutch intensive care unit reduces prescribing errors and related patient harm: an intervention study. Crit Care 2010; 14: R174.
23. Kane SL, Weber RJ, Dasta JF. The impact of critical care pharmacists on enhancing patient outcomes. Intensive Care Med 2003; 29: 691-8.
24. Kane-Gill SL, Kirisci L, Verrico MM, Rothschild JM. Analysis of risk factors for adverse drug events in critically ill patients. Crit Care Med 2012; 40: 823-8.
25. Kucukarslan S N, Peters M, Mlynarek M M, Nafziger D A. Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch Intern Med 2003; 163: 2014-8.
26. Mergenhagen KA, Blum SS, Kugler A, Livote EE, Nebeker JR, Ott MC, et al. Pharmacist- versus physicianinitiated admission medication reconciliation: impact on adverse drug events. Am J Geriatr Pharmacother 2012; 10: 242-50.
27. Matzke GR, Aronoff GR, Atkinson A J Jr, Bennett WM, Decker BS, Eckardt KU, et al. Drug dosing consideration in patients with acute and chronic kidney disease - a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80: 1122-37.